NSG 6005 PHARM WEEKS 1-3 QUIZ (FROM
OPERATION FNP CLASS 11) BASED ON FINAL
EXAM!!
1. Genetic polymorphisms account for differences in metabolism, including:
☐ A. Poor metabolizers, who lack a working enzyme
☐ B. Intermediate metabolizers, who have one working, wild-type allele and one
mutant allele
☐ C. Extensive metabolizers, with two normally functioning alleles
☑ D. All of the above
2. Up to 21% of Asians are ultra-rapid 2D6 metabolizers, leading to:
☐ A. A need to monitor drugs metabolized by 2D6 for toxicity
☑ B. Increased dosages needed of drugs metabolized by 2D6, such as the
selective serotonin reuptake inhibitors
☐ C. Decreased conversion of codeine to morphine by CYP 2D6
☐ D. The need for lowered dosages of drugs, such as beta blockers
3. Rifampin is a nonspecific CYP450 inducer that may:
☐ A. Lead to toxic levels of rifampin and must be monitored closely
☐ B. Cause toxic levels of drugs, such as oral contraceptives, when
coadministered
☑ C. Induce the metabolism of drugs, such as oral contraceptives, leading to
therapeutic failure
☐ D. Cause nonspecific changes in drug metabolism
,4. Inhibition of P-glycoprotein by a drug such as quinidine may lead to:
☐ A. Decreased therapeutic levels of quinidine
☐ B. Increased therapeutic levels of quinidine
☐ C. Decreased levels of a coadministered drug, such as digoxin, that requires P-
glycoprotein for absorption and elimination
☑ D. Increased levels of a coadministered drug, such as digoxin, that requires P-
glycoprotein for absorption and elimination
5. Warfarin resistance may be seen in patients with VCORC1 mutation, leading to:
☐ A. Toxic levels of warfarin building up
☑ B. Decreased response to warfarin
☐ C. Increased risk for significant drug interactions with warfarin
☐ D. Less risk of drug interactions with warfarin
6. Genetic testing for VCORC1 mutation to assess potential warfarin resistance is
required prior to prescribing warfarin.
☐ A. True
☑ B. False
7. Pharmacogenetic testing is required by the U.S. Food and Drug Administration
prior to prescribing:
☐ A. Erythromycin
☐ B. Digoxin
,☑ C. Cetuximab
☐ D. Rifampin
8. Carbamazepine has a Black Box Warning recommending testing for the HLA-
B*1502 allele in patients with Asian ancestry prior to starting therapy due to:
☐ A. Decreased effectiveness of carbamazepine in treating seizures
☐ B. Increased risk for drug interactions
☑ C. Increased risk for Stevens-Johnson syndrome
☐ D. Resistance to carbamazepine
9. A genetic variation in how the metabolite of the cancer drug irinotecan (SN-38)
is inactivated by the body may lead to:
☐ A. Decreased effectiveness of irinotecan
☑ B. Increased adverse drug reactions, such as neutropenia
☐ C. Delayed metabolism of irinotecan into SN-38
☐ D. Concerns of irinotecan being carcinogenic
10. Patients who have a poor metabolism phenotype will have:
☑ A. Slowed metabolism of a prodrug into an active drug, leading to
accumulation of prodrug
☐ B. Accumulation of inactive metabolites
☐ C. A need for increased dosages of medications
☐ D. Increased elimination of active drug
, 11. Ultra-rapid metabolizers of drugs may have:
☐ A. To have dosages adjusted downward to prevent drug accumulation
☑ B. Active drug rapidly metabolized into inactive metabolites, leading to
therapeutic failure
☐ C. Increased elimination of active, nonmetabolized drug
☐ D. Slowed metabolism of a prodrug, leading to accumulation
12. A provider may consider testing for CYP2D6 variants prior to starting
tamoxifen to:
☐ A. Ensure no increased adverse reactions to tamoxifen
☐ B. Identify potential drug-drug interactions
☑ C. Reduce the likelihood of therapeutic failure
☐ D. Identify poor metabolizers of tamoxifen
The most frequent type of drug-food interaction is food:
1. Causing increased therapeutic drug levels
2. Affecting the metabolism of the drug
3. Altering the volume of distribution of drugs
4. Affecting the gastrointestinal absorption of drugs
OPERATION FNP CLASS 11) BASED ON FINAL
EXAM!!
1. Genetic polymorphisms account for differences in metabolism, including:
☐ A. Poor metabolizers, who lack a working enzyme
☐ B. Intermediate metabolizers, who have one working, wild-type allele and one
mutant allele
☐ C. Extensive metabolizers, with two normally functioning alleles
☑ D. All of the above
2. Up to 21% of Asians are ultra-rapid 2D6 metabolizers, leading to:
☐ A. A need to monitor drugs metabolized by 2D6 for toxicity
☑ B. Increased dosages needed of drugs metabolized by 2D6, such as the
selective serotonin reuptake inhibitors
☐ C. Decreased conversion of codeine to morphine by CYP 2D6
☐ D. The need for lowered dosages of drugs, such as beta blockers
3. Rifampin is a nonspecific CYP450 inducer that may:
☐ A. Lead to toxic levels of rifampin and must be monitored closely
☐ B. Cause toxic levels of drugs, such as oral contraceptives, when
coadministered
☑ C. Induce the metabolism of drugs, such as oral contraceptives, leading to
therapeutic failure
☐ D. Cause nonspecific changes in drug metabolism
,4. Inhibition of P-glycoprotein by a drug such as quinidine may lead to:
☐ A. Decreased therapeutic levels of quinidine
☐ B. Increased therapeutic levels of quinidine
☐ C. Decreased levels of a coadministered drug, such as digoxin, that requires P-
glycoprotein for absorption and elimination
☑ D. Increased levels of a coadministered drug, such as digoxin, that requires P-
glycoprotein for absorption and elimination
5. Warfarin resistance may be seen in patients with VCORC1 mutation, leading to:
☐ A. Toxic levels of warfarin building up
☑ B. Decreased response to warfarin
☐ C. Increased risk for significant drug interactions with warfarin
☐ D. Less risk of drug interactions with warfarin
6. Genetic testing for VCORC1 mutation to assess potential warfarin resistance is
required prior to prescribing warfarin.
☐ A. True
☑ B. False
7. Pharmacogenetic testing is required by the U.S. Food and Drug Administration
prior to prescribing:
☐ A. Erythromycin
☐ B. Digoxin
,☑ C. Cetuximab
☐ D. Rifampin
8. Carbamazepine has a Black Box Warning recommending testing for the HLA-
B*1502 allele in patients with Asian ancestry prior to starting therapy due to:
☐ A. Decreased effectiveness of carbamazepine in treating seizures
☐ B. Increased risk for drug interactions
☑ C. Increased risk for Stevens-Johnson syndrome
☐ D. Resistance to carbamazepine
9. A genetic variation in how the metabolite of the cancer drug irinotecan (SN-38)
is inactivated by the body may lead to:
☐ A. Decreased effectiveness of irinotecan
☑ B. Increased adverse drug reactions, such as neutropenia
☐ C. Delayed metabolism of irinotecan into SN-38
☐ D. Concerns of irinotecan being carcinogenic
10. Patients who have a poor metabolism phenotype will have:
☑ A. Slowed metabolism of a prodrug into an active drug, leading to
accumulation of prodrug
☐ B. Accumulation of inactive metabolites
☐ C. A need for increased dosages of medications
☐ D. Increased elimination of active drug
, 11. Ultra-rapid metabolizers of drugs may have:
☐ A. To have dosages adjusted downward to prevent drug accumulation
☑ B. Active drug rapidly metabolized into inactive metabolites, leading to
therapeutic failure
☐ C. Increased elimination of active, nonmetabolized drug
☐ D. Slowed metabolism of a prodrug, leading to accumulation
12. A provider may consider testing for CYP2D6 variants prior to starting
tamoxifen to:
☐ A. Ensure no increased adverse reactions to tamoxifen
☐ B. Identify potential drug-drug interactions
☑ C. Reduce the likelihood of therapeutic failure
☐ D. Identify poor metabolizers of tamoxifen
The most frequent type of drug-food interaction is food:
1. Causing increased therapeutic drug levels
2. Affecting the metabolism of the drug
3. Altering the volume of distribution of drugs
4. Affecting the gastrointestinal absorption of drugs
